Home › Funds › Caligan Partners LP › MBX
Caligan Partners LP position in MBX
MBX BIOSCIENCES INC COM · Health Care
Caligan Partners LP reported holding 200,000 shares of MBX (MBX BIOSCIENCES INC COM) in its Q2 2026 13F filing — a position valued at US$11.0M, representing 0.65% of its reported portfolio and ranking #22 among its reported holdings. Caligan Partners LP has disclosed MBX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Caligan Partners LP's MBX position evolved
Caligan Partners LP first disclosed a stake in MBX in Q1 2026 at 848,590 shares (US$25.3M). Across 2 filings, Caligan Partners LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 200,000 shares valued at US$11.0M — a reduction of -648,590 shares quarter over quarter.. Notable position changes include a 76% trim in Q2 2026 (shares rose 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 848.59K | $25.33M | New |
| Q2 2026 | 200.00K | $11.04M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MBX and 13F data
MBX (MBX BIOSCIENCES INC COM) is a Health Care company. 73 other funds we track also report a position in MBX — the largest reported positions include Frazier Life Sciences Management, L.P. (US$367.2M), NEA Management Company, LLC (US$199.5M), ORBIMED ADVISORS LLC (US$189.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MBX
- Frazier Life Sciences Management, L.P. 6.65M sh · $367.19M · Q2 2026
- NEA Management Company, LLC 3.61M sh · $199.52M · Q2 2026
- ORBIMED ADVISORS LLC 3.43M sh · $189.27M · Q2 2026
- Paradigm Biocapital Advisors LP 2.51M sh · $138.44M · Q2 2026
- NVP Associates, LLC 2.14M sh · $117.93M · Q2 2026
- Deep Track Capital, LP 1.73M sh · $95.64M · Q2 2026
- Aaron Wealth Advisors LLC 1.18M sh · $68.92M · Q3 2026
- Kynam Capital Management, LP 934.80K sh · $51.60M · Q2 2026
- Parkman Healthcare Partners LLC 800.17K sh · $44.17M · Q2 2026
- BRAIDWELL LP 710.88K sh · $39.24M · Q2 2026
- TCG Crossover Management, LLC 650.00K sh · $35.88M · Q2 2026
- Cormorant Asset Management, LP 550.00K sh · $30.36M · Q2 2026
More on Caligan Partners LP
FAQ
How long has Caligan Partners LP held MBX?
Caligan Partners LP has disclosed MBX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Caligan Partners LP's current position in MBX?
As of Q2 2026, Caligan Partners LP holds 200.00K shares of MBX (MBX BIOSCIENCES INC COM), valued at $11.04M, representing 0.65% of its reported portfolio and ranking #22.
Has Caligan Partners LP been buying or selling MBX?
In the latest 13F filing (Q2 2026), Caligan Partners LP reduced its position in MBX.
Which other funds hold MBX?
Other major institutional holders of MBX include Frazier Life Sciences Management, L.P., NEA Management Company, LLC, ORBIMED ADVISORS LLC, among 73 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.